{"gene":"RBM38","run_date":"2026-04-28T19:45:45","timeline":{"discoveries":[{"year":2006,"finding":"RBM38 (RNPC1) directly binds to AU-rich elements in the 3' UTR of p21 mRNA and stabilizes the p21 transcript, maintaining basal and stress-induced p21 levels. The RNPC1a isoform, but not RNPC1b, stabilizes p21 mRNA and induces G1 cell cycle arrest, despite both isoforms binding the 3' UTR.","method":"RNA immunoprecipitation, mRNA stability assay, siRNA knockdown, isoform-specific functional assays","journal":"Genes & Development","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, replicated in subsequent papers","pmids":["17050675"],"is_preprint":false},{"year":2010,"finding":"RBM38 physically interacts with HuR via its RRM domain (interacting with RRM3 of HuR), and this interaction enhances HuR's RNA-binding activity to p21 3'-UTR AU-rich elements; RBM38's ability to regulate p21 mRNA stability is dependent on HuR.","method":"Co-immunoprecipitation, RNA EMSA, in vitro and in vivo RNA binding assays, domain deletion mapping","journal":"Nucleic Acids Research","confidence":"High","confidence_rationale":"Tier 1-2 — reciprocal co-IP, in vitro binding reconstitution, domain mapping","pmids":["20064878"],"is_preprint":false},{"year":2010,"finding":"RBM38 destabilizes p63 mRNA by binding to AU-/U-rich elements in p63 3' UTR via its RRM domain, leading to decreased p63 expression and promoting keratinocyte differentiation.","method":"mRNA stability assay, RNA immunoprecipitation, EMSA, RRM domain mutant, knockdown/overexpression","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including in vitro binding and domain mutagenesis","pmids":["20457941"],"is_preprint":false},{"year":2011,"finding":"RBM38 represses p53 mRNA translation by preventing cap-binding protein eIF4E from binding to p53 mRNA; this requires the C-terminal domain of RBM38 for physical interaction with eIF4E, and the N-terminal RRM domain for binding p53 5' and 3' UTRs.","method":"Polysome profiling, RNA immunoprecipitation, pulldown, domain deletion mutants, reporter assays","journal":"Genes & Development","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods, mechanistic domain dissection, replicated by subsequent studies","pmids":["21764855"],"is_preprint":false},{"year":2011,"finding":"RBM38 selectively inhibits miRNA access to target mRNAs by binding uridine-rich regions near miRNA target sequences, protecting p53 target mRNAs from miRNA-mediated repression while showing lower propensity to block miR-34a action on SIRT1.","method":"Genetic screen, luciferase reporter assay, RNA immunoprecipitation, functional miRNA-target interaction assays","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 2 — genetic screen plus orthogonal functional validation, mechanistic specificity demonstrated","pmids":["22027593"],"is_preprint":false},{"year":2012,"finding":"RBM38 destabilizes MDM2 transcript by binding to multiple AU-/U-rich elements in MDM2 3' UTR, thereby decreasing MDM2 expression independently of p53; RNA-binding activity of RBM38 is required for this effect.","method":"mRNA stability assay, RNA immunoprecipitation, reporter assay, RNA-binding mutant, knockdown/knockout","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including mutant analysis and KO cells","pmids":["22710720"],"is_preprint":false},{"year":2012,"finding":"RBM38 post-transcriptionally stabilizes HuR mRNA by binding its 3' UTR; RNA-binding-deficient RBM38 mutant cannot stabilize HuR, and HuR mediates RBM38-induced growth suppression by repressing c-Myc.","method":"mRNA stability assay, RNA immunoprecipitation, RNA-binding mutant, knockdown/knockout","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple methods, mutant validation, downstream pathway established","pmids":["22371495"],"is_preprint":false},{"year":2012,"finding":"RBM38 expression is directly transcriptionally regulated by E2F1, and RBM38 in turn limits E2F1-induced cell-cycle progression, forming a negative feedback loop; endogenous E2F1 binds the RBM38 promoter.","method":"Chromatin immunoprecipitation, qRT-PCR, Western blot, E2F1 activation system, RBM38 knockdown + cell cycle analysis","journal":"Molecular Cancer Research","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP plus functional cell cycle readout, single lab","pmids":["22798430"],"is_preprint":false},{"year":2012,"finding":"RBM38 regulates p73 mRNA stability by binding a CU-rich element in the p73 3' UTR; loss of RNPC1 in p53-null MEFs reduces p73 expression and decreases cellular senescence.","method":"mRNA stability assay, RNA immunoprecipitation, EMSA, knockout MEFs, cellular senescence assay","journal":"Molecular and Cellular Biology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods with functional genetic validation","pmids":["22508983"],"is_preprint":false},{"year":2013,"finding":"RBM38 stabilizes MIC-1 mRNA by binding to an AU-rich element in the MIC-1 3' UTR, and MIC-1 is required for RBM38-induced cell growth suppression.","method":"mRNA stability assay, RNA immunoprecipitation, ARE-binding assay, knockdown","journal":"Journal of Biological Chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — multiple methods but single lab","pmids":["23836903"],"is_preprint":false},{"year":2013,"finding":"RBM38 is phosphorylated at Ser195 by GSK3, and this phosphorylation abolishes the RBM38-eIF4E interaction on p53 mRNA; phosphorylated RBM38 or phosphomimetic S195D instead interacts with eIF4G to promote assembly of the eIF4F complex and enhance p53 mRNA translation. Inhibition of PI3K-Akt activates GSK3, leading to increased RBM38 phosphorylation and elevated p53.","method":"In vitro kinase assay, phosphomimetic/non-phosphorylatable mutants, RNA immunoprecipitation, co-immunoprecipitation, reporter assay, PI3K pathway inhibition","journal":"Genes & Development","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay combined with multiple mutant and pathway analyses","pmids":["24142875"],"is_preprint":false},{"year":2013,"finding":"RBM38 regulates alternative splicing during late erythroid differentiation, activating Protein 4.1R (EPB41) exon 16 inclusion. SELEX-Seq identified a GU-rich RBM38 binding motif, and tethering assays showed RBM38 can directly activate splicing when recruited downstream of an exon.","method":"Exon junction microarray, minigene splicing assay, SELEX-Seq, tethering assay, erythroid differentiation model","journal":"PLoS ONE","confidence":"High","confidence_rationale":"Tier 1-2 — multiple complementary methods including SELEX-Seq and tethering assay","pmids":["24250749"],"is_preprint":false},{"year":2014,"finding":"Rbm38-null mice exhibit accelerated aging, hematopoietic defects, and spontaneous tumors; Rbm38 deficiency enhances p53 accumulation after ionizing radiation in vivo, and markedly decreases tumor penetrance in p53-heterozygous mice via enhanced p53 expression, providing genetic evidence that the p53-Rbm38 autoregulatory loop operates in vivo.","method":"Rbm38 knockout mouse model, ionizing radiation challenge, tumor monitoring, genetic epistasis with p53 alleles","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic model with multiple epistasis experiments","pmids":["25512531"],"is_preprint":false},{"year":2015,"finding":"PPM1D phosphatase directly interacts with and dephosphorylates RBM38 at Ser195, reversing GSK3-mediated phosphorylation; this dephosphorylation restores RBM38's ability to suppress p53 mRNA translation. RBM38 in turn promotes PPM1D mRNA translation by binding PPM1D 3' UTR.","method":"Co-immunoprecipitation, in vitro dephosphorylation assay, reporter assay, RNA immunoprecipitation","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 — in vitro dephosphorylation with multiple supporting functional assays","pmids":["25823026"],"is_preprint":false},{"year":2015,"finding":"RBM38 regulates HIF1α expression via mRNA translation: RBM38 binds HIF1α 5' and 3' UTRs and prevents eIF4E from binding HIF1α mRNA, reducing HIF1α protein synthesis under hypoxic conditions.","method":"Metabolic labeling (de novo protein synthesis), RNA immunoprecipitation, eIF4E-mRNA binding assay, reporter assay","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — multiple methods including translational rate measurement, single lab","pmids":["25622105"],"is_preprint":false},{"year":2017,"finding":"RBM38 stabilizes PTEN mRNA by binding to multiple AU/U-rich elements in PTEN 3' UTR, increasing PTEN expression; RBM38-mediated growth suppression in breast cancer is partly dependent on PTEN.","method":"RNA immunoprecipitation, EMSA, luciferase reporter assay, siRNA, mRNA stability assay","journal":"Journal of Experimental & Clinical Cancer Research","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal binding and functional assays, single lab","pmids":["29052531"],"is_preprint":false},{"year":2017,"finding":"RBM38 stabilizes ZO-1 mRNA by binding to AU/U-rich elements in its 3' UTR; TGF-β-induced transcription repressor Snail directly suppresses RBM38 expression by binding E-box elements in the RBM38 promoter, thereby reducing ZO-1 and promoting EMT.","method":"Chromatin immunoprecipitation, luciferase reporter assay, RNA immunoprecipitation, EMSA, Transwell migration assay","journal":"British Journal of Cancer","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and RNA binding assays with functional validation, single lab","pmids":["28683467"],"is_preprint":false},{"year":2017,"finding":"c-Myc directly represses RBM38 transcription by binding E-box motifs in the RBM38 promoter; RBM38 in turn destabilizes c-Myc mRNA by binding AU-rich elements in c-Myc 3' UTR, forming a mutually antagonistic feedback loop.","method":"Chromatin immunoprecipitation, luciferase reporter assay, RNA immunoprecipitation, mRNA stability assay","journal":"Journal of Experimental & Clinical Cancer Research","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and RNA binding assays, single lab","pmids":["28399911"],"is_preprint":false},{"year":2018,"finding":"Synthetic peptide Pep8 (8 amino acids from RBM38) disrupts the RBM38-eIF4E complex; Ser-6 of Pep8 forms a hydrogen bond with Asp-202 in eIF4E. Disruption of this complex relieves p53 mRNA translational repression and suppresses tumor growth in an RBM38- and p53-dependent manner.","method":"Molecular simulation, peptide binding assay, co-immunoprecipitation, colony formation, xenograft tumor model","journal":"Cancer Research","confidence":"High","confidence_rationale":"Tier 1-2 — structural modeling combined with in vitro and in vivo functional validation","pmids":["30591552"],"is_preprint":false},{"year":2018,"finding":"Rbm38 stabilizes Pten mRNA through an AU-rich element in Pten 3' UTR; loss of Rbm38 in mutant p53 knock-in mice decreases Pten expression and promotes T-cell lymphomagenesis, demonstrating that Rbm38 jointly modulates mutant p53 and Pten in vivo.","method":"Rbm38 knockout mice crossed with mutant p53 knock-in, mRNA stability assay, luciferase reporter assay, tumor incidence monitoring","journal":"Cancer Research","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic model with mechanistic mRNA stability validation","pmids":["29330147"],"is_preprint":false},{"year":2018,"finding":"Ser195 phosphorylation of RBM38 by GSK3β disrupts its association with the Ago2-miR203 complex, thereby preventing miR203-mediated degradation of p63α mRNA and increasing p63 expression; non-phosphorylatable RBM38-S195A promotes Ago2-miR203-dependent p63 mRNA decay, whereas phosphomimetic S195D does not.","method":"Phosphomimetic/non-phosphorylatable knock-in MEFs, co-immunoprecipitation with Ago2, GSK3β activation, RT-qPCR","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — knock-in cell lines with multiple orthogonal methods establishing phosphorylation-dependent Ago2 interaction","pmids":["30567739"],"is_preprint":false},{"year":2018,"finding":"The Rbm38-p63 negative feedback loop controls aging and tumorigenesis in vivo: compound Rbm38-/-;TAp63+/- mice have extended lifespan and reduced tumor incidence compared to single mutants, and show reduced expression of inflammatory cytokines IL17D and Tnfsf15.","method":"Compound knockout mouse model, lifespan analysis, tumor incidence monitoring, cytokine expression analysis","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in vivo with multiple phenotypic readouts","pmids":["29520104"],"is_preprint":false},{"year":2018,"finding":"RBM38 facilitates HBV pgRNA packaging by directly binding the lower bulge of the epsilon (ε) stem-loop via its RNP submotifs, interacting with HBV Pol in an RNA-independent manner, forming heterogeneous oligomers with RBM24, and binding HBV core protein via its C-terminal ARD domain.","method":"RNA immunoprecipitation, co-immunoprecipitation, in vitro RNA binding assay, domain deletion analysis","journal":"Antiviral Research","confidence":"Medium","confidence_rationale":"Tier 2 — multiple binding assays with domain mapping, single lab","pmids":["35041910"],"is_preprint":false},{"year":2020,"finding":"Crystal structure of the RRM domain of human RBM38 in complex with single-stranded RNA revealed that RBM38 recognizes G(U/C/A)GUG sequences; two phenylalanine residues stack with RNA bases and a series of hydrogen bonds determine sequence-specific recognition.","method":"X-ray crystallography, mutagenesis of key residues, RNA binding assays","journal":"Biochemical Journal","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with mutagenesis validation","pmids":["31860021"],"is_preprint":false},{"year":2021,"finding":"RBM38 exerts opposing effects on survivin expression: it blocks let-7b-mediated survivin mRNA degradation (protecting survivin) while also interacting with AGO2 to facilitate miR-203a-mediated survivin mRNA degradation. Ser-195 in RBM38 interacts with Glu-73/-76 in AGO2; Pep8 blocks the RBM38-AGO2 interaction.","method":"RNA immunoprecipitation, co-immunoprecipitation, luciferase reporter assay, mutant analysis (S195-AGO2 interaction), Pep8 peptide treatment","journal":"Cancer Research","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods with mutagenesis defining protein-protein interaction interface","pmids":["33472892"],"is_preprint":false},{"year":2021,"finding":"Fine-tuning of RBM38-eIF4E interaction controls p53 expression in vivo: knock-in of RBM38-S195D enhances eIF4E binding to p53 mRNA and p53 expression, while knock-in of eIF4E-D202K weakens RBM38 interaction and enhances p53. S193D knock-in mice have shortened lifespan and are prone to spontaneous tumors and chronic inflammation.","method":"Multiple knock-in cell lines and mouse model (Rbm38-S193D KI), RNA immunoprecipitation of eIF4E, p53 expression analysis, lifespan monitoring","journal":"Genes & Development","confidence":"High","confidence_rationale":"Tier 2 — knock-in mouse model plus multiple cell line KI validations","pmids":["33664057"],"is_preprint":false},{"year":2023,"finding":"TRIM17 E3 ubiquitin ligase interacts with RBM38 and promotes K48-linked polyubiquitination and proteasomal degradation of RBM38, thereby mediating cisplatin resistance in NSCLC.","method":"Co-immunoprecipitation, ubiquitination assay (K48-linkage specific), knockdown/overexpression, in vitro and in vivo resistance assays","journal":"Cellular Oncology","confidence":"Medium","confidence_rationale":"Tier 2 — K48-linked ubiquitination assay plus functional reversal, single lab","pmids":["37219768"],"is_preprint":false},{"year":2023,"finding":"CDK4 phosphorylates RBM38 at Ser195, which enhances mutant p53 mRNA translation by promoting eIF4G interaction; CDK4/6 inhibitors reduce this phosphorylation and thereby suppress mutant p53 translation.","method":"In vitro kinase assay, phosphomimetic mutants, RNA immunoprecipitation, Western blot in CDK4/6 inhibitor-treated cells","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 1-2 — in vitro kinase assay plus functional validation, single lab","pmids":["41154395"],"is_preprint":false},{"year":2023,"finding":"CBX7 positively regulates RBM38 expression in cardiomyocytes via TARDBP in a TARDBP-dependent manner; overexpression of RBM38 inhibits proliferation of CBX7-depleted cardiomyocytes, placing RBM38 downstream of the CBX7-TARDBP axis in cell cycle exit.","method":"Co-immunoprecipitation, mass spectrometry, adenoviral overexpression, genetic KO mice (Tnnt2-Cre;Cbx7), neonatal cardiomyocyte proliferation assay","journal":"Circulation","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP/MS plus functional genetic epistasis, single lab","pmids":["37158107"],"is_preprint":false},{"year":2009,"finding":"RBM38 binds to p21 transcript in vivo in myoblasts, and overexpression of RBM38 induces cell cycle arrest and promotes myogenic differentiation; knockdown of RBM38 suppresses cell cycle arrest and delays differentiation in C2C12 cells, and this effect is rescued by p21 overexpression.","method":"Immunoprecipitation-RT-PCR (RIP), RNA interference, overexpression, myogenic differentiation assay, p21 rescue experiment","journal":"Genes to Cells","confidence":"Medium","confidence_rationale":"Tier 2 — RIP plus genetic rescue experiment establishing p21-dependence","pmids":["19817877"],"is_preprint":false},{"year":2018,"finding":"RBM38 binds to ISE2 (5'-UGUGUG-3') in parvovirus B19 pre-mRNA and promotes splicing at the D2 donor site required for 11-kDa protein expression; knockdown of RBM38 decreases D2-spliced mRNA encoding the 11-kDa protein but not VP2, thereby reducing viral DNA replication.","method":"In vitro RNA binding assay (EMSA), RBM38 knockdown, RT-PCR of splice isoforms, viral replication assay","journal":"Journal of Virology","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro binding combined with specific splicing knockdown, single lab","pmids":["29437973"],"is_preprint":false},{"year":2025,"finding":"Rbm38 regulates erythroid terminal differentiation by controlling alternative splicing, mRNA decay, and translation of ferrochelatase (Fech); Rbm38-deficient mice develop microcytic hypochromic anemia, protoporphyrin IX accumulation resembling erythropoietic protoporphyria, and enforced Fech expression rescues erythroid defects.","method":"Whole-body and conditional Rbm38 knockout mice, RNA-seq splicing analysis, mRNA stability assay, translational assay, Fech rescue transplantation","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple RNA regulatory mechanisms demonstrated in vivo with genetic rescue","pmids":["40961234"],"is_preprint":false}],"current_model":"RBM38 (RNPC1) is an RNA-binding protein that uses its GU/AU/U-rich element-recognizing RRM domain (structure resolved by crystallography) to regulate mRNA stability, translation, and alternative splicing of a broad set of targets including p53, p21, p63, p73, MDM2, HuR, PTEN, HIF1α, and ferrochelatase; its key regulatory switch is phosphorylation at Ser195 by GSK3 (reversed by PPM1D phosphatase) and by CDK4, which toggles RBM38 between suppressing p53 translation (via blocking eIF4E–mRNA cap interaction) and promoting it (via eIF4G recruitment), and phosphorylation also controls its association with the Ago2-miRNA complex to modulate miRNA-mediated mRNA degradation; RBM38 forms feedback loops with p53, p63, p73, MDM2, c-Myc, and E2F1, is targeted for K48-linked ubiquitin-mediated degradation by TRIM17 and RNF26, and in vivo genetic studies establish it as a tumor suppressor and essential regulator of hematopoiesis and erythropoiesis."},"narrative":{"teleology":[{"year":2006,"claim":"The first mechanistic function of RBM38 was established: it directly binds AU-rich elements in the p21 3′ UTR and stabilizes p21 mRNA, thereby linking an RNA-binding protein to G1 cell-cycle arrest — an activity specific to the RNPC1a isoform.","evidence":"RNA immunoprecipitation, mRNA stability assays, isoform-specific functional assays in human cell lines","pmids":["17050675"],"confidence":"High","gaps":["mechanism of isoform-specific functional difference unresolved","whether RBM38 binds p21 mRNA directly in a reconstituted system was not yet shown"]},{"year":2009,"claim":"RBM38 was shown to function beyond cancer cell lines: in myoblasts it binds p21 mRNA, induces cell-cycle arrest, and promotes myogenic differentiation in a p21-dependent manner, establishing a role in skeletal muscle lineage commitment.","evidence":"RIP, knockdown/overexpression in C2C12 cells, p21 rescue experiment","pmids":["19817877"],"confidence":"Medium","gaps":["in vivo muscle phenotype not examined","whether other differentiation targets exist was unknown"]},{"year":2010,"claim":"The mechanism by which RBM38 stabilizes p21 mRNA was refined: RBM38 physically interacts with HuR via their respective RRM domains, enhancing HuR binding to p21 3′ UTR ARE, while RBM38 was simultaneously found to destabilize p63 mRNA through its own RRM-dependent binding — revealing target-specific opposing regulatory outcomes.","evidence":"Reciprocal co-IP, in vitro RNA EMSA, domain deletion mapping for HuR; mRNA stability and RIP assays for p63","pmids":["20064878","20457941"],"confidence":"High","gaps":["structural basis for target-specific stabilization versus destabilization unknown","whether RBM38 recruits different effectors to different targets was not addressed"]},{"year":2011,"claim":"A fundamentally new regulatory mode was discovered: RBM38 represses p53 mRNA translation by blocking eIF4E binding to the mRNA cap, using its C-terminal domain for eIF4E interaction and its RRM for UTR binding — establishing RBM38 as a translational repressor, not only an mRNA stability factor.","evidence":"Polysome profiling, domain deletion mutants, eIF4E pulldown, reporter assays","pmids":["21764855"],"confidence":"High","gaps":["whether this translation-repression mechanism applies to other targets was untested","structural details of the RBM38–eIF4E interface unresolved"]},{"year":2011,"claim":"RBM38 was found to selectively antagonize miRNA access to target mRNAs by binding uridine-rich regions near miRNA target sites, adding miRNA-mediated repression modulation as a third regulatory mechanism.","evidence":"Genetic screen, luciferase reporters, RIP, miRNA-target interaction assays","pmids":["22027593"],"confidence":"High","gaps":["genome-wide scope of miRNA antagonism unclear","whether RBM38 directly competes with RISC or alters mRNA structure was not distinguished"]},{"year":2012,"claim":"The target repertoire expanded to include MDM2, HuR, p73, and E2F1: RBM38 destabilizes MDM2 and c-Myc transcripts, stabilizes HuR and p73 mRNAs, and is itself transcriptionally regulated by E2F1 — revealing multiple feedback loops placing RBM38 at a hub of p53-family and cell-cycle regulatory networks.","evidence":"mRNA stability assays, RIP, RNA-binding mutants, KO MEFs, ChIP of E2F1 on RBM38 promoter","pmids":["22710720","22371495","22508983","22798430"],"confidence":"High","gaps":["hierarchy among feedback loops unresolved","whether HuR cooperation generalizes beyond p21 was not tested"]},{"year":2013,"claim":"The critical regulatory switch was identified: GSK3β phosphorylates RBM38 at Ser195, converting it from an eIF4E-binding translational repressor to an eIF4G-recruiting translational activator of p53, linking PI3K-Akt signaling to p53 expression control.","evidence":"In vitro kinase assay, phosphomimetic/non-phosphorylatable mutants, co-IP, PI3K inhibition","pmids":["24142875"],"confidence":"High","gaps":["whether Ser195 phosphorylation affects all targets or is p53-specific was unknown","in vivo consequences of the phospho-switch were not yet tested"]},{"year":2013,"claim":"A splicing-regulatory function was established: RBM38 activates EPB41 exon 16 inclusion during erythroid differentiation, and SELEX-Seq defined a GU-rich binding motif — expanding its role to alternative splicing in hematopoiesis.","evidence":"Exon junction microarray, minigene, SELEX-Seq, tethering assay, erythroid differentiation model","pmids":["24250749"],"confidence":"High","gaps":["full spectrum of splicing targets during erythropoiesis unknown","mechanism of splicing activation versus repression by RBM38 was not defined"]},{"year":2014,"claim":"Rbm38-knockout mice provided the first in vivo genetic validation: loss of Rbm38 causes accelerated aging, hematopoietic defects, and spontaneous tumors, while enhancing p53-dependent tumor suppression in p53-heterozygous mice — confirming the p53-RBM38 autoregulatory loop functions physiologically.","evidence":"Rbm38 KO mouse, ionizing radiation challenge, genetic epistasis with p53 alleles, tumor monitoring","pmids":["25512531"],"confidence":"High","gaps":["tissue-specific contributions to aging phenotype unresolved","whether tumor phenotype is entirely p53-mediated was not determined"]},{"year":2015,"claim":"PPM1D was identified as the phosphatase that reverses GSK3-mediated Ser195 phosphorylation, restoring translational repression of p53, and RBM38 reciprocally promotes PPM1D mRNA translation — closing an additional feedback loop governing the phospho-switch.","evidence":"In vitro dephosphorylation, co-IP, RIP, reporter assays","pmids":["25823026"],"confidence":"High","gaps":["whether other phosphatases act on Ser195 in specific tissues was untested"]},{"year":2018,"claim":"The Ser195 phospho-switch was shown to control RBM38's interaction with the Ago2–miRNA complex: phosphorylation disrupts Ago2 binding, preventing miR-203-mediated p63 mRNA degradation, while genetic epistasis in compound Rbm38/TAp63 knockout mice demonstrated that the RBM38-p63 feedback loop governs aging and tumorigenesis in vivo.","evidence":"S195A/S195D knock-in MEFs, co-IP with Ago2, compound KO mice, lifespan and tumor monitoring","pmids":["30567739","29520104"],"confidence":"High","gaps":["whether phospho-dependent Ago2 modulation extends to miRNAs beyond miR-203 was not systematically tested"]},{"year":2018,"claim":"A synthetic peptide (Pep8) derived from 8 amino acids of RBM38 was shown to disrupt the RBM38–eIF4E complex and relieve p53 translational repression, suppressing tumor growth in xenografts in an RBM38- and p53-dependent manner — providing pharmacological validation of the translational control mechanism.","evidence":"Molecular simulation, peptide binding assay, co-IP, xenograft tumor model","pmids":["30591552"],"confidence":"High","gaps":["peptide pharmacokinetics and clinical translatability not addressed","whether Pep8 also disrupts RBM38–Ago2 interaction was not initially clear"]},{"year":2020,"claim":"The crystal structure of the RBM38 RRM domain bound to RNA resolved the molecular basis of sequence specificity: two phenylalanines stack with RNA bases and hydrogen bonds specify G(U/C/A)GUG recognition — providing the first atomic-level understanding of target selection.","evidence":"X-ray crystallography with mutagenesis validation and RNA binding assays","pmids":["31860021"],"confidence":"High","gaps":["structure of full-length RBM38 including C-terminal eIF4E-binding region unsolved","how RRM recognizes diverse AU-rich versus GU-rich elements structurally was not reconciled"]},{"year":2021,"claim":"The Pep8 peptide was shown to also block the RBM38–AGO2 interaction via the Ser195–Glu73/76 interface, and knock-in mice carrying RBM38-S193D or eIF4E-D202K mutations confirmed that fine-tuning of the RBM38–eIF4E interaction controls p53 levels, lifespan, and tumor susceptibility in vivo.","evidence":"Multiple knock-in mouse models, RIP of eIF4E, lifespan monitoring, Pep8 co-IP disruption","pmids":["33472892","33664057"],"confidence":"High","gaps":["how phospho-RBM38 simultaneously coordinates eIF4G recruitment and Ago2 release on the same target is mechanistically unclear"]},{"year":2023,"claim":"CDK4 was identified as a second kinase phosphorylating RBM38 at Ser195, promoting mutant p53 translation via eIF4G; TRIM17 E3 ligase was shown to target RBM38 for K48-linked ubiquitin-dependent degradation, mediating cisplatin resistance — revealing additional layers of RBM38 regulation.","evidence":"In vitro kinase assay for CDK4, CDK4/6 inhibitor treatment; co-IP and K48-specific ubiquitination assays for TRIM17","pmids":["41154395","37219768"],"confidence":"Medium","gaps":["whether CDK4 and GSK3β act redundantly or in different contexts is unresolved","TRIM17-mediated degradation confirmed in single lab only","other E3 ligases targeting RBM38 not systematically surveyed"]},{"year":2025,"claim":"RBM38 was established as an essential regulator of erythroid terminal differentiation by jointly controlling alternative splicing, mRNA decay, and translation of ferrochelatase (Fech); Rbm38-deficient mice develop microcytic hypochromic anemia with protoporphyrin IX accumulation resembling erythropoietic protoporphyria, rescued by enforced Fech expression.","evidence":"Conditional Rbm38 KO mice, RNA-seq splicing analysis, mRNA stability and translation assays, Fech rescue transplantation","pmids":["40961234"],"confidence":"High","gaps":["whether RBM38 mutations cause erythropoietic protoporphyria in humans is unknown","full complement of erythroid splicing targets beyond EPB41 and Fech not defined"]},{"year":null,"claim":"Key unresolved questions include: the structural basis for how RBM38 switches between mRNA stabilization and destabilization on different targets; the full-length protein structure including the C-terminal eIF4E/eIF4G-binding and Ago2-interacting regions; tissue-specific hierarchies among the multiple feedback loops; and whether human RBM38 loss-of-function mutations cause hematologic disease.","evidence":"","pmids":[],"confidence":"Low","gaps":["no full-length RBM38 structure available","no human genetic disease association established","systematic transcriptome-wide identification of direct splicing versus stability versus translation targets not completed"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[0,1,2,3,4,5,6,8,11,23]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[3,10,20,24,25]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[11,30,31]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3,10,24]}],"pathway":[{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[0,2,5,6,8,11,30,31]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[3,10,13,25,27]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[0,7,29]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[8,12]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[2,11,29,31]}],"complexes":[],"partners":["HUR","EIF4E","EIF4G","AGO2","PPM1D","TRIM17","GSK3B","RBM24"],"other_free_text":[]},"mechanistic_narrative":"RBM38 (RNPC1) is an RNA-binding protein that functions as a central post-transcriptional regulator of cell cycle, differentiation, and tumor suppression by controlling the mRNA stability, translation, and alternative splicing of key targets including p53, p21, p63, p73, MDM2, PTEN, HuR, HIF1α, c-Myc, and ferrochelatase [PMID:17050675, PMID:21764855, PMID:20457941, PMID:22508983, PMID:22710720, PMID:29052531, PMID:25622105, PMID:28399911, PMID:40961234]. Its single RRM domain recognizes GU/AU/U-rich elements in target 3′ UTRs and 5′ UTRs, and its C-terminal domain physically interacts with eIF4E to block cap-dependent translation initiation; phosphorylation at Ser195 by GSK3β or CDK4 switches RBM38 from an eIF4E-sequestering translational repressor to an eIF4G-recruiting translational activator of p53, and also controls its association with the Ago2–miRNA machinery to modulate miRNA-mediated mRNA decay [PMID:24142875, PMID:30567739, PMID:33472892, PMID:41154395, PMID:25823026, PMID:31860021]. RBM38 operates within autoregulatory feedback loops with p53, p63, p73, E2F1, and c-Myc, is targeted for K48-linked ubiquitin-dependent degradation by TRIM17, and its protein levels and phosphorylation status are reversed by PPM1D phosphatase [PMID:22798430, PMID:28399911, PMID:29520104, PMID:37219768, PMID:25823026]. Rbm38-knockout mice develop accelerated aging, spontaneous tumors, hematopoietic defects, and microcytic hypochromic anemia with protoporphyrin IX accumulation resembling erythropoietic protoporphyria, rescued by enforced ferrochelatase expression [PMID:25512531, PMID:40961234]."},"prefetch_data":{"uniprot":{"accession":"Q9H0Z9","full_name":"RNA-binding protein 38","aliases":["CLL-associated antigen KW-5","HSRNASEB","RNA-binding motif protein 38","RNA-binding region-containing protein 1","ssDNA-binding protein SEB4"],"length_aa":239,"mass_kda":25.5,"function":"RNA-binding protein that specifically bind the 3'-UTR of CDKN1A transcripts, leading to maintain the stability of CDKN1A transcripts, thereby acting as a mediator of the p53/TP53 family to regulate CDKN1A. CDKN1A is a cyclin-dependent kinase inhibitor transcriptionally regulated by the p53/TP53 family to induce cell cycle arrest. Isoform 1, but not isoform 2, has the ability to induce cell cycle arrest in G1 and maintain the stability of CDKN1A transcripts induced by p53/TP53. Also acts as a mRNA splicing factor. Specifically regulates the expression of FGFR2-IIIb, an epithelial cell-specific isoform of FGFR2. Plays a role in myogenic differentiation (Microbial infection) Essential factor for the splicing of the pre-mRNAs of human parvovirus B19 (B19V) and for the expression of B19V 11-kDa protein, which enhances viral replication","subcellular_location":"Cytoplasm, cytosol; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9H0Z9/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RBM38","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000132819","cell_line_id":"CID001483","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"nucleoplasm","grade":2}],"interactors":[{"gene":"RBM38;RBM24","stoichiometry":10.0},{"gene":"RAF1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001483","total_profiled":1310},"omim":[{"mim_id":"617603","title":"RNA-BINDING MOTIF PROTEIN 24; RBM24","url":"https://www.omim.org/entry/617603"},{"mim_id":"612428","title":"RNA-BINDING MOTIF PROTEIN 38; RBM38","url":"https://www.omim.org/entry/612428"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"bone marrow","ntpm":251.7},{"tissue":"skeletal muscle","ntpm":261.1}],"url":"https://www.proteinatlas.org/search/RBM38"},"hgnc":{"alias_symbol":["HSRNASEB","SEB4D","seb4B","dJ800J21.2"],"prev_symbol":["RNPC1"]},"alphafold":{"accession":"Q9H0Z9","domains":[{"cath_id":"3.30.70.330","chopping":"34-109","consensus_level":"high","plddt":94.2104,"start":34,"end":109}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H0Z9","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H0Z9-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H0Z9-F1-predicted_aligned_error_v6.png","plddt_mean":67.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RBM38","jax_strain_url":"https://www.jax.org/strain/search?query=RBM38"},"sequence":{"accession":"Q9H0Z9","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9H0Z9.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9H0Z9/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H0Z9"}},"corpus_meta":[{"pmid":"17050675","id":"PMC_17050675","title":"RNPC1, an RNA-binding protein and a target of the p53 family, is required for maintaining the stability of the basal and stress-induced p21 transcript.","date":"2006","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/17050675","citation_count":124,"is_preprint":false},{"pmid":"21764855","id":"PMC_21764855","title":"Translational repression of p53 by RNPC1, a p53 target overexpressed in lymphomas.","date":"2011","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/21764855","citation_count":117,"is_preprint":false},{"pmid":"20064878","id":"PMC_20064878","title":"RNPC1 modulates the RNA-binding activity of, and cooperates with, HuR to regulate p21 mRNA stability.","date":"2010","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/20064878","citation_count":101,"is_preprint":false},{"pmid":"22027593","id":"PMC_22027593","title":"Selective inhibition of microRNA accessibility by RBM38 is required for p53 activity.","date":"2011","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/22027593","citation_count":84,"is_preprint":false},{"pmid":"20457941","id":"PMC_20457941","title":"RNPC1, an RNA-binding protein and a target of the p53 family, regulates p63 expression through mRNA stability.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20457941","citation_count":75,"is_preprint":false},{"pmid":"25512531","id":"PMC_25512531","title":"Mice deficient in Rbm38, a target of the p53 family, are susceptible to accelerated aging and spontaneous tumors.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25512531","citation_count":64,"is_preprint":false},{"pmid":"19817877","id":"PMC_19817877","title":"RNA-binding proteins Rbm38 and Rbm24 regulate myogenic differentiation via p21-dependent and -independent regulatory pathways.","date":"2009","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/19817877","citation_count":60,"is_preprint":false},{"pmid":"24142875","id":"PMC_24142875","title":"Glycogen synthase kinase 3 promotes p53 mRNA translation via phosphorylation of RNPC1.","date":"2013","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/24142875","citation_count":55,"is_preprint":false},{"pmid":"22508983","id":"PMC_22508983","title":"p73 expression is regulated by RNPC1, a target of the p53 family, via mRNA stability.","date":"2012","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22508983","citation_count":51,"is_preprint":false},{"pmid":"29052531","id":"PMC_29052531","title":"PTEN expression is upregulated by a RNA-binding protein RBM38 via enhancing its mRNA stability in breast cancer.","date":"2017","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/29052531","citation_count":48,"is_preprint":false},{"pmid":"30176896","id":"PMC_30176896","title":"RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.","date":"2018","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/30176896","citation_count":48,"is_preprint":false},{"pmid":"24250749","id":"PMC_24250749","title":"The RNA binding protein RBM38 (RNPC1) regulates splicing during late erythroid differentiation.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24250749","citation_count":44,"is_preprint":false},{"pmid":"22710720","id":"PMC_22710720","title":"MDM2 expression is repressed by the RNA-binding protein RNPC1 via mRNA stability.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22710720","citation_count":43,"is_preprint":false},{"pmid":"28683467","id":"PMC_28683467","title":"RBM38 is involved in TGF-β-induced epithelial-to-mesenchymal transition by stabilising zonula occludens-1 mRNA in breast cancer.","date":"2017","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28683467","citation_count":42,"is_preprint":false},{"pmid":"24884756","id":"PMC_24884756","title":"RNA-binding protein RNPC1: acting as a tumor suppressor in breast cancer.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24884756","citation_count":41,"is_preprint":false},{"pmid":"30591552","id":"PMC_30591552","title":"Disruption of the Rbm38-eIF4E Complex with a Synthetic Peptide Pep8 Increases p53 Expression.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30591552","citation_count":39,"is_preprint":false},{"pmid":"29733656","id":"PMC_29733656","title":"RNA Binding Protein RNPC1 Inhibits Breast Cancer Cell Metastasis via Activating STARD13-Correlated ceRNA Network.","date":"2018","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/29733656","citation_count":36,"is_preprint":false},{"pmid":"22371495","id":"PMC_22371495","title":"The RNA-binding protein RNPC1 stabilizes the mRNA encoding the RNA-binding protein HuR and cooperates with HuR to suppress cell proliferation.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22371495","citation_count":35,"is_preprint":false},{"pmid":"28399911","id":"PMC_28399911","title":"The role of c-Myc-RBM38 loop in the growth suppression in breast cancer.","date":"2017","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/28399911","citation_count":34,"is_preprint":false},{"pmid":"22798430","id":"PMC_22798430","title":"RBM38 is a direct transcriptional target of E2F1 that limits E2F1-induced proliferation.","date":"2012","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/22798430","citation_count":30,"is_preprint":false},{"pmid":"26740055","id":"PMC_26740055","title":"The RNA binding proteins RBM38 and DND1 are repressed in AML and have a novel function in APL differentiation.","date":"2015","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/26740055","citation_count":29,"is_preprint":false},{"pmid":"29330147","id":"PMC_29330147","title":"Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant p53 by Downregulating PTEN.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29330147","citation_count":28,"is_preprint":false},{"pmid":"23836903","id":"PMC_23836903","title":"RNPC1, an RNA-binding protein and a p53 target, regulates macrophage inhibitory cytokine-1 (MIC-1) expression through mRNA stability.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23836903","citation_count":28,"is_preprint":false},{"pmid":"22214381","id":"PMC_22214381","title":"Radiation sensitivity of esophageal adenocarcinoma: the contribution of the RNA-binding protein RNPC1 and p21-mediated cell cycle arrest to radioresistance.","date":"2012","source":"Radiation research","url":"https://pubmed.ncbi.nlm.nih.gov/22214381","citation_count":27,"is_preprint":false},{"pmid":"25823026","id":"PMC_25823026","title":"PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25823026","citation_count":25,"is_preprint":false},{"pmid":"34751998","id":"PMC_34751998","title":"miR-125a-5p increases cellular DNA damage of aging males and perturbs stage-specific embryo development via Rbm38-p53 signaling.","date":"2021","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/34751998","citation_count":24,"is_preprint":false},{"pmid":"25622105","id":"PMC_25622105","title":"Hypoxia-inducible factor 1 alpha is regulated by RBM38, a RNA-binding protein and a p53 family target, via mRNA translation.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25622105","citation_count":23,"is_preprint":false},{"pmid":"25881544","id":"PMC_25881544","title":"Estrogen receptor (ER) was regulated by RNPC1 stabilizing mRNA in ER positive breast cancer.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25881544","citation_count":22,"is_preprint":false},{"pmid":"32642788","id":"PMC_32642788","title":"RBM38 in cancer: role and mechanism.","date":"2020","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/32642788","citation_count":21,"is_preprint":false},{"pmid":"28459215","id":"PMC_28459215","title":"The expression of RNA-binding protein RBM38 decreased in renal cell carcinoma and represses renal cancer cell proliferation, migration, and invasion.","date":"2017","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28459215","citation_count":21,"is_preprint":false},{"pmid":"29437973","id":"PMC_29437973","title":"RNA Binding Protein RBM38 Regulates Expression of the 11-Kilodalton Protein of Parvovirus B19, Which Facilitates Viral DNA Replication.","date":"2018","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/29437973","citation_count":20,"is_preprint":false},{"pmid":"29520104","id":"PMC_29520104","title":"The Rbm38-p63 feedback loop is critical for tumor suppression and longevity.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29520104","citation_count":19,"is_preprint":false},{"pmid":"34453780","id":"PMC_34453780","title":"RNA-binding protein RBM38 inhibits colorectal cancer progression by partly and competitively binding to PTEN 3'UTR with miR-92a-3p.","date":"2021","source":"Environmental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/34453780","citation_count":19,"is_preprint":false},{"pmid":"37158107","id":"PMC_37158107","title":"Polycomb Group Protein CBX7 Represses Cardiomyocyte Proliferation Through Modulation of the TARDBP/RBM38 Axis.","date":"2023","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/37158107","citation_count":18,"is_preprint":false},{"pmid":"29288351","id":"PMC_29288351","title":"RNPC1 inhibits non-small cell lung cancer progression via regulating miR-181a/CASC2 axis.","date":"2017","source":"Biotechnology letters","url":"https://pubmed.ncbi.nlm.nih.gov/29288351","citation_count":17,"is_preprint":false},{"pmid":"27634883","id":"PMC_27634883","title":"RNPC1 enhances progesterone receptor functions by regulating its mRNA stability in breast cancer.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27634883","citation_count":17,"is_preprint":false},{"pmid":"37219768","id":"PMC_37219768","title":"TRIM17-mediated ubiquitination and degradation of RBM38 promotes cisplatin resistance in non-small cell lung cancer.","date":"2023","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/37219768","citation_count":15,"is_preprint":false},{"pmid":"26046131","id":"PMC_26046131","title":"Integrative genomic analyses of the RNA-binding protein, RNPC1, and its potential role in cancer prediction.","date":"2015","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26046131","citation_count":14,"is_preprint":false},{"pmid":"32774357","id":"PMC_32774357","title":"Alternative Splicing of Cdh23 Exon 68 Is Regulated by RBM24, RBM38, and PTBP1.","date":"2020","source":"Neural plasticity","url":"https://pubmed.ncbi.nlm.nih.gov/32774357","citation_count":14,"is_preprint":false},{"pmid":"28850611","id":"PMC_28850611","title":"The RNA-binding protein Rbm38 is dispensable during pressure overload-induced cardiac remodeling in mice.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28850611","citation_count":13,"is_preprint":false},{"pmid":"30567739","id":"PMC_30567739","title":"Serine 195 phosphorylation in the RNA-binding protein Rbm38 increases p63 expression by modulating Rbm38's interaction with the Ago2-miR203 complex.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30567739","citation_count":13,"is_preprint":false},{"pmid":"35351042","id":"PMC_35351042","title":"LncRNA CALML3-AS1 suppresses papillary thyroid cancer progression via sponging miR-20a-5p/RBM38 axis.","date":"2022","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35351042","citation_count":12,"is_preprint":false},{"pmid":"29108232","id":"PMC_29108232","title":"TAp63γ and ΔNp63γ are regulated by RBM38 via mRNA stability and have an opposing function in growth suppression.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29108232","citation_count":12,"is_preprint":false},{"pmid":"30843048","id":"PMC_30843048","title":"Therapeutic modulation of RNA-binding protein Rbm38 facilitates re-endothelialization after arterial injury.","date":"2019","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/30843048","citation_count":10,"is_preprint":false},{"pmid":"31860021","id":"PMC_31860021","title":"Structural basis for mRNA recognition by human RBM38.","date":"2020","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/31860021","citation_count":10,"is_preprint":false},{"pmid":"35041910","id":"PMC_35041910","title":"RNA-Binding motif protein 38 (RBM38) mediates HBV pgRNA packaging into the nucleocapsid.","date":"2022","source":"Antiviral research","url":"https://pubmed.ncbi.nlm.nih.gov/35041910","citation_count":9,"is_preprint":false},{"pmid":"32088727","id":"PMC_32088727","title":"RNA Binding Protein RNPC1 Suppresses the Stemness of Human Endometrial Cancer Cells via Stabilizing MST1/2 mRNA.","date":"2020","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/32088727","citation_count":8,"is_preprint":false},{"pmid":"33664057","id":"PMC_33664057","title":"Fine-tuning p53 activity by modulating the interaction between eukaryotic translation initiation factor eIF4E and RNA-binding protein RBM38.","date":"2021","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/33664057","citation_count":8,"is_preprint":false},{"pmid":"31966462","id":"PMC_31966462","title":"RNA-binding protein RBM38 acts as a tumor suppressor in gastric cancer.","date":"2017","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31966462","citation_count":7,"is_preprint":false},{"pmid":"34868364","id":"PMC_34868364","title":"RBM38 is negatively regulated by miR-320b and enhances Adriamycin resistance in breast cancer cells.","date":"2021","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/34868364","citation_count":7,"is_preprint":false},{"pmid":"37296859","id":"PMC_37296859","title":"RBM38 Reverses Sorafenib Resistance in Hepatocellular Carcinoma Cells by Combining and Promoting lncRNA-GAS5.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/37296859","citation_count":7,"is_preprint":false},{"pmid":"36940176","id":"PMC_36940176","title":"Identification of a First-in-Class Small-Molecule Inhibitor of the EIF4E-RBM38 Complex That Enhances Wild-type TP53 Protein Translation for Tumor Growth Suppression.","date":"2023","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/36940176","citation_count":7,"is_preprint":false},{"pmid":"31760527","id":"PMC_31760527","title":"RBM38 induces SIRT1 expression during hypoxia in non-small cell lung cancer cells by suppressing MIR34A expression.","date":"2019","source":"Biotechnology letters","url":"https://pubmed.ncbi.nlm.nih.gov/31760527","citation_count":7,"is_preprint":false},{"pmid":"32862581","id":"PMC_32862581","title":"Roles of ZEB2 and RBM38 in liver cancer stem cell proliferation.","date":"2020","source":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32862581","citation_count":6,"is_preprint":false},{"pmid":"33472892","id":"PMC_33472892","title":"Survivin Expression Is Differentially Regulated by a Selective Cross-talk between RBM38 and miRNAs let-7b or miR-203a.","date":"2021","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33472892","citation_count":6,"is_preprint":false},{"pmid":"34302858","id":"PMC_34302858","title":"RNA-binding protein RNPC1 acts as an oncogene in gastric cancer by stabilizing aurora kinase B mRNA.","date":"2021","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/34302858","citation_count":5,"is_preprint":false},{"pmid":"37099788","id":"PMC_37099788","title":"RNF26 Promotes Pancreatic Cancer Proliferation by Enhancing RBM38 Degradation.","date":"2023","source":"Pancreas","url":"https://pubmed.ncbi.nlm.nih.gov/37099788","citation_count":3,"is_preprint":false},{"pmid":"35574389","id":"PMC_35574389","title":"Optimization of eIF4E-Binding Peptide Pep8 to Disrupt the RBM38-eIF4E Complex for Induction of p53 and Tumor Suppression.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35574389","citation_count":3,"is_preprint":false},{"pmid":"33233740","id":"PMC_33233740","title":"Rbm38 Reduces the Transcription Elongation Defect of the SMEK2 Gene Caused by Splicing Deficiency.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33233740","citation_count":3,"is_preprint":false},{"pmid":"34204113","id":"PMC_34204113","title":"Small Proline-Rich Protein 2A and 2D Are Regulated by the RBM38-p73 Axis and Associated with p73-Dependent Suppression of Chronic Inflammation.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34204113","citation_count":3,"is_preprint":false},{"pmid":"26988821","id":"PMC_26988821","title":"[RNPC1 induces sensitivity of HER-2-positive breast cancer BT474 cells to trastuzumab through upregulation of HER2].","date":"2016","source":"Zhonghua zhong liu za zhi [Chinese journal of oncology]","url":"https://pubmed.ncbi.nlm.nih.gov/26988821","citation_count":2,"is_preprint":false},{"pmid":"40961234","id":"PMC_40961234","title":"Rbm38 deficiency impairs erythroid heme biosynthesis and induces porphyria via reduced ferrochelatase expression.","date":"2025","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/40961234","citation_count":1,"is_preprint":false},{"pmid":"40796306","id":"PMC_40796306","title":"RNA-binding protein Rbm38 as a multifaceted post-transcriptional regulator in zebrafish pancreatic development.","date":"2026","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/40796306","citation_count":0,"is_preprint":false},{"pmid":"40527976","id":"PMC_40527976","title":"EIF4A3-Mediated downregulation of circPTEN promotes hepatocellular carcinoma progression through the miR-1289/RBM38 Axis.","date":"2025","source":"Journal of molecular histology","url":"https://pubmed.ncbi.nlm.nih.gov/40527976","citation_count":0,"is_preprint":false},{"pmid":"34893109","id":"PMC_34893109","title":"[RBM38 Mediates the Proliferation of Acute Myeloid Leukemia Cells HL-60 by Regulating FZD1 mRNA Stability].","date":"2021","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/34893109","citation_count":0,"is_preprint":false},{"pmid":"41154395","id":"PMC_41154395","title":"CDK4/6 Inhibitors Suppress RB-Null Triple-Negative Breast Cancer by Inhibiting Mutant P53 Expression via RBM38 RNA-Binding Protein.","date":"2025","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/41154395","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.01.10.632466","title":"Identification and classification of abundant RNA-binding proteins in the mouse lens and interactions of Carhsp1, Igf2bp1/ZBP1, and Ybx1 with crystallin and β-actin mRNAs","date":"2025-01-11","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.10.632466","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":35208,"output_tokens":6992,"usd":0.105252},"stage2":{"model":"claude-opus-4-6","input_tokens":10743,"output_tokens":4365,"usd":0.24426},"total_usd":0.349512,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"RBM38 (RNPC1) directly binds to AU-rich elements in the 3' UTR of p21 mRNA and stabilizes the p21 transcript, maintaining basal and stress-induced p21 levels. The RNPC1a isoform, but not RNPC1b, stabilizes p21 mRNA and induces G1 cell cycle arrest, despite both isoforms binding the 3' UTR.\",\n      \"method\": \"RNA immunoprecipitation, mRNA stability assay, siRNA knockdown, isoform-specific functional assays\",\n      \"journal\": \"Genes & Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, replicated in subsequent papers\",\n      \"pmids\": [\"17050675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RBM38 physically interacts with HuR via its RRM domain (interacting with RRM3 of HuR), and this interaction enhances HuR's RNA-binding activity to p21 3'-UTR AU-rich elements; RBM38's ability to regulate p21 mRNA stability is dependent on HuR.\",\n      \"method\": \"Co-immunoprecipitation, RNA EMSA, in vitro and in vivo RNA binding assays, domain deletion mapping\",\n      \"journal\": \"Nucleic Acids Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reciprocal co-IP, in vitro binding reconstitution, domain mapping\",\n      \"pmids\": [\"20064878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RBM38 destabilizes p63 mRNA by binding to AU-/U-rich elements in p63 3' UTR via its RRM domain, leading to decreased p63 expression and promoting keratinocyte differentiation.\",\n      \"method\": \"mRNA stability assay, RNA immunoprecipitation, EMSA, RRM domain mutant, knockdown/overexpression\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including in vitro binding and domain mutagenesis\",\n      \"pmids\": [\"20457941\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"RBM38 represses p53 mRNA translation by preventing cap-binding protein eIF4E from binding to p53 mRNA; this requires the C-terminal domain of RBM38 for physical interaction with eIF4E, and the N-terminal RRM domain for binding p53 5' and 3' UTRs.\",\n      \"method\": \"Polysome profiling, RNA immunoprecipitation, pulldown, domain deletion mutants, reporter assays\",\n      \"journal\": \"Genes & Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods, mechanistic domain dissection, replicated by subsequent studies\",\n      \"pmids\": [\"21764855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"RBM38 selectively inhibits miRNA access to target mRNAs by binding uridine-rich regions near miRNA target sequences, protecting p53 target mRNAs from miRNA-mediated repression while showing lower propensity to block miR-34a action on SIRT1.\",\n      \"method\": \"Genetic screen, luciferase reporter assay, RNA immunoprecipitation, functional miRNA-target interaction assays\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic screen plus orthogonal functional validation, mechanistic specificity demonstrated\",\n      \"pmids\": [\"22027593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"RBM38 destabilizes MDM2 transcript by binding to multiple AU-/U-rich elements in MDM2 3' UTR, thereby decreasing MDM2 expression independently of p53; RNA-binding activity of RBM38 is required for this effect.\",\n      \"method\": \"mRNA stability assay, RNA immunoprecipitation, reporter assay, RNA-binding mutant, knockdown/knockout\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including mutant analysis and KO cells\",\n      \"pmids\": [\"22710720\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"RBM38 post-transcriptionally stabilizes HuR mRNA by binding its 3' UTR; RNA-binding-deficient RBM38 mutant cannot stabilize HuR, and HuR mediates RBM38-induced growth suppression by repressing c-Myc.\",\n      \"method\": \"mRNA stability assay, RNA immunoprecipitation, RNA-binding mutant, knockdown/knockout\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods, mutant validation, downstream pathway established\",\n      \"pmids\": [\"22371495\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"RBM38 expression is directly transcriptionally regulated by E2F1, and RBM38 in turn limits E2F1-induced cell-cycle progression, forming a negative feedback loop; endogenous E2F1 binds the RBM38 promoter.\",\n      \"method\": \"Chromatin immunoprecipitation, qRT-PCR, Western blot, E2F1 activation system, RBM38 knockdown + cell cycle analysis\",\n      \"journal\": \"Molecular Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus functional cell cycle readout, single lab\",\n      \"pmids\": [\"22798430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"RBM38 regulates p73 mRNA stability by binding a CU-rich element in the p73 3' UTR; loss of RNPC1 in p53-null MEFs reduces p73 expression and decreases cellular senescence.\",\n      \"method\": \"mRNA stability assay, RNA immunoprecipitation, EMSA, knockout MEFs, cellular senescence assay\",\n      \"journal\": \"Molecular and Cellular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods with functional genetic validation\",\n      \"pmids\": [\"22508983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RBM38 stabilizes MIC-1 mRNA by binding to an AU-rich element in the MIC-1 3' UTR, and MIC-1 is required for RBM38-induced cell growth suppression.\",\n      \"method\": \"mRNA stability assay, RNA immunoprecipitation, ARE-binding assay, knockdown\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods but single lab\",\n      \"pmids\": [\"23836903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RBM38 is phosphorylated at Ser195 by GSK3, and this phosphorylation abolishes the RBM38-eIF4E interaction on p53 mRNA; phosphorylated RBM38 or phosphomimetic S195D instead interacts with eIF4G to promote assembly of the eIF4F complex and enhance p53 mRNA translation. Inhibition of PI3K-Akt activates GSK3, leading to increased RBM38 phosphorylation and elevated p53.\",\n      \"method\": \"In vitro kinase assay, phosphomimetic/non-phosphorylatable mutants, RNA immunoprecipitation, co-immunoprecipitation, reporter assay, PI3K pathway inhibition\",\n      \"journal\": \"Genes & Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay combined with multiple mutant and pathway analyses\",\n      \"pmids\": [\"24142875\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RBM38 regulates alternative splicing during late erythroid differentiation, activating Protein 4.1R (EPB41) exon 16 inclusion. SELEX-Seq identified a GU-rich RBM38 binding motif, and tethering assays showed RBM38 can directly activate splicing when recruited downstream of an exon.\",\n      \"method\": \"Exon junction microarray, minigene splicing assay, SELEX-Seq, tethering assay, erythroid differentiation model\",\n      \"journal\": \"PLoS ONE\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple complementary methods including SELEX-Seq and tethering assay\",\n      \"pmids\": [\"24250749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Rbm38-null mice exhibit accelerated aging, hematopoietic defects, and spontaneous tumors; Rbm38 deficiency enhances p53 accumulation after ionizing radiation in vivo, and markedly decreases tumor penetrance in p53-heterozygous mice via enhanced p53 expression, providing genetic evidence that the p53-Rbm38 autoregulatory loop operates in vivo.\",\n      \"method\": \"Rbm38 knockout mouse model, ionizing radiation challenge, tumor monitoring, genetic epistasis with p53 alleles\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic model with multiple epistasis experiments\",\n      \"pmids\": [\"25512531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PPM1D phosphatase directly interacts with and dephosphorylates RBM38 at Ser195, reversing GSK3-mediated phosphorylation; this dephosphorylation restores RBM38's ability to suppress p53 mRNA translation. RBM38 in turn promotes PPM1D mRNA translation by binding PPM1D 3' UTR.\",\n      \"method\": \"Co-immunoprecipitation, in vitro dephosphorylation assay, reporter assay, RNA immunoprecipitation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro dephosphorylation with multiple supporting functional assays\",\n      \"pmids\": [\"25823026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"RBM38 regulates HIF1α expression via mRNA translation: RBM38 binds HIF1α 5' and 3' UTRs and prevents eIF4E from binding HIF1α mRNA, reducing HIF1α protein synthesis under hypoxic conditions.\",\n      \"method\": \"Metabolic labeling (de novo protein synthesis), RNA immunoprecipitation, eIF4E-mRNA binding assay, reporter assay\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods including translational rate measurement, single lab\",\n      \"pmids\": [\"25622105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"RBM38 stabilizes PTEN mRNA by binding to multiple AU/U-rich elements in PTEN 3' UTR, increasing PTEN expression; RBM38-mediated growth suppression in breast cancer is partly dependent on PTEN.\",\n      \"method\": \"RNA immunoprecipitation, EMSA, luciferase reporter assay, siRNA, mRNA stability assay\",\n      \"journal\": \"Journal of Experimental & Clinical Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal binding and functional assays, single lab\",\n      \"pmids\": [\"29052531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"RBM38 stabilizes ZO-1 mRNA by binding to AU/U-rich elements in its 3' UTR; TGF-β-induced transcription repressor Snail directly suppresses RBM38 expression by binding E-box elements in the RBM38 promoter, thereby reducing ZO-1 and promoting EMT.\",\n      \"method\": \"Chromatin immunoprecipitation, luciferase reporter assay, RNA immunoprecipitation, EMSA, Transwell migration assay\",\n      \"journal\": \"British Journal of Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and RNA binding assays with functional validation, single lab\",\n      \"pmids\": [\"28683467\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"c-Myc directly represses RBM38 transcription by binding E-box motifs in the RBM38 promoter; RBM38 in turn destabilizes c-Myc mRNA by binding AU-rich elements in c-Myc 3' UTR, forming a mutually antagonistic feedback loop.\",\n      \"method\": \"Chromatin immunoprecipitation, luciferase reporter assay, RNA immunoprecipitation, mRNA stability assay\",\n      \"journal\": \"Journal of Experimental & Clinical Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and RNA binding assays, single lab\",\n      \"pmids\": [\"28399911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Synthetic peptide Pep8 (8 amino acids from RBM38) disrupts the RBM38-eIF4E complex; Ser-6 of Pep8 forms a hydrogen bond with Asp-202 in eIF4E. Disruption of this complex relieves p53 mRNA translational repression and suppresses tumor growth in an RBM38- and p53-dependent manner.\",\n      \"method\": \"Molecular simulation, peptide binding assay, co-immunoprecipitation, colony formation, xenograft tumor model\",\n      \"journal\": \"Cancer Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — structural modeling combined with in vitro and in vivo functional validation\",\n      \"pmids\": [\"30591552\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Rbm38 stabilizes Pten mRNA through an AU-rich element in Pten 3' UTR; loss of Rbm38 in mutant p53 knock-in mice decreases Pten expression and promotes T-cell lymphomagenesis, demonstrating that Rbm38 jointly modulates mutant p53 and Pten in vivo.\",\n      \"method\": \"Rbm38 knockout mice crossed with mutant p53 knock-in, mRNA stability assay, luciferase reporter assay, tumor incidence monitoring\",\n      \"journal\": \"Cancer Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic model with mechanistic mRNA stability validation\",\n      \"pmids\": [\"29330147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Ser195 phosphorylation of RBM38 by GSK3β disrupts its association with the Ago2-miR203 complex, thereby preventing miR203-mediated degradation of p63α mRNA and increasing p63 expression; non-phosphorylatable RBM38-S195A promotes Ago2-miR203-dependent p63 mRNA decay, whereas phosphomimetic S195D does not.\",\n      \"method\": \"Phosphomimetic/non-phosphorylatable knock-in MEFs, co-immunoprecipitation with Ago2, GSK3β activation, RT-qPCR\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — knock-in cell lines with multiple orthogonal methods establishing phosphorylation-dependent Ago2 interaction\",\n      \"pmids\": [\"30567739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The Rbm38-p63 negative feedback loop controls aging and tumorigenesis in vivo: compound Rbm38-/-;TAp63+/- mice have extended lifespan and reduced tumor incidence compared to single mutants, and show reduced expression of inflammatory cytokines IL17D and Tnfsf15.\",\n      \"method\": \"Compound knockout mouse model, lifespan analysis, tumor incidence monitoring, cytokine expression analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo with multiple phenotypic readouts\",\n      \"pmids\": [\"29520104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"RBM38 facilitates HBV pgRNA packaging by directly binding the lower bulge of the epsilon (ε) stem-loop via its RNP submotifs, interacting with HBV Pol in an RNA-independent manner, forming heterogeneous oligomers with RBM24, and binding HBV core protein via its C-terminal ARD domain.\",\n      \"method\": \"RNA immunoprecipitation, co-immunoprecipitation, in vitro RNA binding assay, domain deletion analysis\",\n      \"journal\": \"Antiviral Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple binding assays with domain mapping, single lab\",\n      \"pmids\": [\"35041910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Crystal structure of the RRM domain of human RBM38 in complex with single-stranded RNA revealed that RBM38 recognizes G(U/C/A)GUG sequences; two phenylalanine residues stack with RNA bases and a series of hydrogen bonds determine sequence-specific recognition.\",\n      \"method\": \"X-ray crystallography, mutagenesis of key residues, RNA binding assays\",\n      \"journal\": \"Biochemical Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mutagenesis validation\",\n      \"pmids\": [\"31860021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"RBM38 exerts opposing effects on survivin expression: it blocks let-7b-mediated survivin mRNA degradation (protecting survivin) while also interacting with AGO2 to facilitate miR-203a-mediated survivin mRNA degradation. Ser-195 in RBM38 interacts with Glu-73/-76 in AGO2; Pep8 blocks the RBM38-AGO2 interaction.\",\n      \"method\": \"RNA immunoprecipitation, co-immunoprecipitation, luciferase reporter assay, mutant analysis (S195-AGO2 interaction), Pep8 peptide treatment\",\n      \"journal\": \"Cancer Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods with mutagenesis defining protein-protein interaction interface\",\n      \"pmids\": [\"33472892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Fine-tuning of RBM38-eIF4E interaction controls p53 expression in vivo: knock-in of RBM38-S195D enhances eIF4E binding to p53 mRNA and p53 expression, while knock-in of eIF4E-D202K weakens RBM38 interaction and enhances p53. S193D knock-in mice have shortened lifespan and are prone to spontaneous tumors and chronic inflammation.\",\n      \"method\": \"Multiple knock-in cell lines and mouse model (Rbm38-S193D KI), RNA immunoprecipitation of eIF4E, p53 expression analysis, lifespan monitoring\",\n      \"journal\": \"Genes & Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — knock-in mouse model plus multiple cell line KI validations\",\n      \"pmids\": [\"33664057\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TRIM17 E3 ubiquitin ligase interacts with RBM38 and promotes K48-linked polyubiquitination and proteasomal degradation of RBM38, thereby mediating cisplatin resistance in NSCLC.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay (K48-linkage specific), knockdown/overexpression, in vitro and in vivo resistance assays\",\n      \"journal\": \"Cellular Oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — K48-linked ubiquitination assay plus functional reversal, single lab\",\n      \"pmids\": [\"37219768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CDK4 phosphorylates RBM38 at Ser195, which enhances mutant p53 mRNA translation by promoting eIF4G interaction; CDK4/6 inhibitors reduce this phosphorylation and thereby suppress mutant p53 translation.\",\n      \"method\": \"In vitro kinase assay, phosphomimetic mutants, RNA immunoprecipitation, Western blot in CDK4/6 inhibitor-treated cells\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro kinase assay plus functional validation, single lab\",\n      \"pmids\": [\"41154395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CBX7 positively regulates RBM38 expression in cardiomyocytes via TARDBP in a TARDBP-dependent manner; overexpression of RBM38 inhibits proliferation of CBX7-depleted cardiomyocytes, placing RBM38 downstream of the CBX7-TARDBP axis in cell cycle exit.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, adenoviral overexpression, genetic KO mice (Tnnt2-Cre;Cbx7), neonatal cardiomyocyte proliferation assay\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP/MS plus functional genetic epistasis, single lab\",\n      \"pmids\": [\"37158107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"RBM38 binds to p21 transcript in vivo in myoblasts, and overexpression of RBM38 induces cell cycle arrest and promotes myogenic differentiation; knockdown of RBM38 suppresses cell cycle arrest and delays differentiation in C2C12 cells, and this effect is rescued by p21 overexpression.\",\n      \"method\": \"Immunoprecipitation-RT-PCR (RIP), RNA interference, overexpression, myogenic differentiation assay, p21 rescue experiment\",\n      \"journal\": \"Genes to Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RIP plus genetic rescue experiment establishing p21-dependence\",\n      \"pmids\": [\"19817877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"RBM38 binds to ISE2 (5'-UGUGUG-3') in parvovirus B19 pre-mRNA and promotes splicing at the D2 donor site required for 11-kDa protein expression; knockdown of RBM38 decreases D2-spliced mRNA encoding the 11-kDa protein but not VP2, thereby reducing viral DNA replication.\",\n      \"method\": \"In vitro RNA binding assay (EMSA), RBM38 knockdown, RT-PCR of splice isoforms, viral replication assay\",\n      \"journal\": \"Journal of Virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro binding combined with specific splicing knockdown, single lab\",\n      \"pmids\": [\"29437973\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Rbm38 regulates erythroid terminal differentiation by controlling alternative splicing, mRNA decay, and translation of ferrochelatase (Fech); Rbm38-deficient mice develop microcytic hypochromic anemia, protoporphyrin IX accumulation resembling erythropoietic protoporphyria, and enforced Fech expression rescues erythroid defects.\",\n      \"method\": \"Whole-body and conditional Rbm38 knockout mice, RNA-seq splicing analysis, mRNA stability assay, translational assay, Fech rescue transplantation\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple RNA regulatory mechanisms demonstrated in vivo with genetic rescue\",\n      \"pmids\": [\"40961234\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RBM38 (RNPC1) is an RNA-binding protein that uses its GU/AU/U-rich element-recognizing RRM domain (structure resolved by crystallography) to regulate mRNA stability, translation, and alternative splicing of a broad set of targets including p53, p21, p63, p73, MDM2, HuR, PTEN, HIF1α, and ferrochelatase; its key regulatory switch is phosphorylation at Ser195 by GSK3 (reversed by PPM1D phosphatase) and by CDK4, which toggles RBM38 between suppressing p53 translation (via blocking eIF4E–mRNA cap interaction) and promoting it (via eIF4G recruitment), and phosphorylation also controls its association with the Ago2-miRNA complex to modulate miRNA-mediated mRNA degradation; RBM38 forms feedback loops with p53, p63, p73, MDM2, c-Myc, and E2F1, is targeted for K48-linked ubiquitin-mediated degradation by TRIM17 and RNF26, and in vivo genetic studies establish it as a tumor suppressor and essential regulator of hematopoiesis and erythropoiesis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"RBM38 (RNPC1) is an RNA-binding protein that functions as a central post-transcriptional regulator of cell cycle, differentiation, and tumor suppression by controlling the mRNA stability, translation, and alternative splicing of key targets including p53, p21, p63, p73, MDM2, PTEN, HuR, HIF1α, c-Myc, and ferrochelatase [PMID:17050675, PMID:21764855, PMID:20457941, PMID:22508983, PMID:22710720, PMID:29052531, PMID:25622105, PMID:28399911, PMID:40961234]. Its single RRM domain recognizes GU/AU/U-rich elements in target 3′ UTRs and 5′ UTRs, and its C-terminal domain physically interacts with eIF4E to block cap-dependent translation initiation; phosphorylation at Ser195 by GSK3β or CDK4 switches RBM38 from an eIF4E-sequestering translational repressor to an eIF4G-recruiting translational activator of p53, and also controls its association with the Ago2–miRNA machinery to modulate miRNA-mediated mRNA decay [PMID:24142875, PMID:30567739, PMID:33472892, PMID:41154395, PMID:25823026, PMID:31860021]. RBM38 operates within autoregulatory feedback loops with p53, p63, p73, E2F1, and c-Myc, is targeted for K48-linked ubiquitin-dependent degradation by TRIM17, and its protein levels and phosphorylation status are reversed by PPM1D phosphatase [PMID:22798430, PMID:28399911, PMID:29520104, PMID:37219768, PMID:25823026]. Rbm38-knockout mice develop accelerated aging, spontaneous tumors, hematopoietic defects, and microcytic hypochromic anemia with protoporphyrin IX accumulation resembling erythropoietic protoporphyria, rescued by enforced ferrochelatase expression [PMID:25512531, PMID:40961234].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"The first mechanistic function of RBM38 was established: it directly binds AU-rich elements in the p21 3′ UTR and stabilizes p21 mRNA, thereby linking an RNA-binding protein to G1 cell-cycle arrest — an activity specific to the RNPC1a isoform.\",\n      \"evidence\": \"RNA immunoprecipitation, mRNA stability assays, isoform-specific functional assays in human cell lines\",\n      \"pmids\": [\"17050675\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"mechanism of isoform-specific functional difference unresolved\", \"whether RBM38 binds p21 mRNA directly in a reconstituted system was not yet shown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"RBM38 was shown to function beyond cancer cell lines: in myoblasts it binds p21 mRNA, induces cell-cycle arrest, and promotes myogenic differentiation in a p21-dependent manner, establishing a role in skeletal muscle lineage commitment.\",\n      \"evidence\": \"RIP, knockdown/overexpression in C2C12 cells, p21 rescue experiment\",\n      \"pmids\": [\"19817877\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"in vivo muscle phenotype not examined\", \"whether other differentiation targets exist was unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"The mechanism by which RBM38 stabilizes p21 mRNA was refined: RBM38 physically interacts with HuR via their respective RRM domains, enhancing HuR binding to p21 3′ UTR ARE, while RBM38 was simultaneously found to destabilize p63 mRNA through its own RRM-dependent binding — revealing target-specific opposing regulatory outcomes.\",\n      \"evidence\": \"Reciprocal co-IP, in vitro RNA EMSA, domain deletion mapping for HuR; mRNA stability and RIP assays for p63\",\n      \"pmids\": [\"20064878\", \"20457941\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"structural basis for target-specific stabilization versus destabilization unknown\", \"whether RBM38 recruits different effectors to different targets was not addressed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"A fundamentally new regulatory mode was discovered: RBM38 represses p53 mRNA translation by blocking eIF4E binding to the mRNA cap, using its C-terminal domain for eIF4E interaction and its RRM for UTR binding — establishing RBM38 as a translational repressor, not only an mRNA stability factor.\",\n      \"evidence\": \"Polysome profiling, domain deletion mutants, eIF4E pulldown, reporter assays\",\n      \"pmids\": [\"21764855\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"whether this translation-repression mechanism applies to other targets was untested\", \"structural details of the RBM38–eIF4E interface unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"RBM38 was found to selectively antagonize miRNA access to target mRNAs by binding uridine-rich regions near miRNA target sites, adding miRNA-mediated repression modulation as a third regulatory mechanism.\",\n      \"evidence\": \"Genetic screen, luciferase reporters, RIP, miRNA-target interaction assays\",\n      \"pmids\": [\"22027593\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"genome-wide scope of miRNA antagonism unclear\", \"whether RBM38 directly competes with RISC or alters mRNA structure was not distinguished\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"The target repertoire expanded to include MDM2, HuR, p73, and E2F1: RBM38 destabilizes MDM2 and c-Myc transcripts, stabilizes HuR and p73 mRNAs, and is itself transcriptionally regulated by E2F1 — revealing multiple feedback loops placing RBM38 at a hub of p53-family and cell-cycle regulatory networks.\",\n      \"evidence\": \"mRNA stability assays, RIP, RNA-binding mutants, KO MEFs, ChIP of E2F1 on RBM38 promoter\",\n      \"pmids\": [\"22710720\", \"22371495\", \"22508983\", \"22798430\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"hierarchy among feedback loops unresolved\", \"whether HuR cooperation generalizes beyond p21 was not tested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"The critical regulatory switch was identified: GSK3β phosphorylates RBM38 at Ser195, converting it from an eIF4E-binding translational repressor to an eIF4G-recruiting translational activator of p53, linking PI3K-Akt signaling to p53 expression control.\",\n      \"evidence\": \"In vitro kinase assay, phosphomimetic/non-phosphorylatable mutants, co-IP, PI3K inhibition\",\n      \"pmids\": [\"24142875\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"whether Ser195 phosphorylation affects all targets or is p53-specific was unknown\", \"in vivo consequences of the phospho-switch were not yet tested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"A splicing-regulatory function was established: RBM38 activates EPB41 exon 16 inclusion during erythroid differentiation, and SELEX-Seq defined a GU-rich binding motif — expanding its role to alternative splicing in hematopoiesis.\",\n      \"evidence\": \"Exon junction microarray, minigene, SELEX-Seq, tethering assay, erythroid differentiation model\",\n      \"pmids\": [\"24250749\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"full spectrum of splicing targets during erythropoiesis unknown\", \"mechanism of splicing activation versus repression by RBM38 was not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Rbm38-knockout mice provided the first in vivo genetic validation: loss of Rbm38 causes accelerated aging, hematopoietic defects, and spontaneous tumors, while enhancing p53-dependent tumor suppression in p53-heterozygous mice — confirming the p53-RBM38 autoregulatory loop functions physiologically.\",\n      \"evidence\": \"Rbm38 KO mouse, ionizing radiation challenge, genetic epistasis with p53 alleles, tumor monitoring\",\n      \"pmids\": [\"25512531\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"tissue-specific contributions to aging phenotype unresolved\", \"whether tumor phenotype is entirely p53-mediated was not determined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"PPM1D was identified as the phosphatase that reverses GSK3-mediated Ser195 phosphorylation, restoring translational repression of p53, and RBM38 reciprocally promotes PPM1D mRNA translation — closing an additional feedback loop governing the phospho-switch.\",\n      \"evidence\": \"In vitro dephosphorylation, co-IP, RIP, reporter assays\",\n      \"pmids\": [\"25823026\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"whether other phosphatases act on Ser195 in specific tissues was untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"The Ser195 phospho-switch was shown to control RBM38's interaction with the Ago2–miRNA complex: phosphorylation disrupts Ago2 binding, preventing miR-203-mediated p63 mRNA degradation, while genetic epistasis in compound Rbm38/TAp63 knockout mice demonstrated that the RBM38-p63 feedback loop governs aging and tumorigenesis in vivo.\",\n      \"evidence\": \"S195A/S195D knock-in MEFs, co-IP with Ago2, compound KO mice, lifespan and tumor monitoring\",\n      \"pmids\": [\"30567739\", \"29520104\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"whether phospho-dependent Ago2 modulation extends to miRNAs beyond miR-203 was not systematically tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"A synthetic peptide (Pep8) derived from 8 amino acids of RBM38 was shown to disrupt the RBM38–eIF4E complex and relieve p53 translational repression, suppressing tumor growth in xenografts in an RBM38- and p53-dependent manner — providing pharmacological validation of the translational control mechanism.\",\n      \"evidence\": \"Molecular simulation, peptide binding assay, co-IP, xenograft tumor model\",\n      \"pmids\": [\"30591552\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"peptide pharmacokinetics and clinical translatability not addressed\", \"whether Pep8 also disrupts RBM38–Ago2 interaction was not initially clear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"The crystal structure of the RBM38 RRM domain bound to RNA resolved the molecular basis of sequence specificity: two phenylalanines stack with RNA bases and hydrogen bonds specify G(U/C/A)GUG recognition — providing the first atomic-level understanding of target selection.\",\n      \"evidence\": \"X-ray crystallography with mutagenesis validation and RNA binding assays\",\n      \"pmids\": [\"31860021\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"structure of full-length RBM38 including C-terminal eIF4E-binding region unsolved\", \"how RRM recognizes diverse AU-rich versus GU-rich elements structurally was not reconciled\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The Pep8 peptide was shown to also block the RBM38–AGO2 interaction via the Ser195–Glu73/76 interface, and knock-in mice carrying RBM38-S193D or eIF4E-D202K mutations confirmed that fine-tuning of the RBM38–eIF4E interaction controls p53 levels, lifespan, and tumor susceptibility in vivo.\",\n      \"evidence\": \"Multiple knock-in mouse models, RIP of eIF4E, lifespan monitoring, Pep8 co-IP disruption\",\n      \"pmids\": [\"33472892\", \"33664057\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"how phospho-RBM38 simultaneously coordinates eIF4G recruitment and Ago2 release on the same target is mechanistically unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"CDK4 was identified as a second kinase phosphorylating RBM38 at Ser195, promoting mutant p53 translation via eIF4G; TRIM17 E3 ligase was shown to target RBM38 for K48-linked ubiquitin-dependent degradation, mediating cisplatin resistance — revealing additional layers of RBM38 regulation.\",\n      \"evidence\": \"In vitro kinase assay for CDK4, CDK4/6 inhibitor treatment; co-IP and K48-specific ubiquitination assays for TRIM17\",\n      \"pmids\": [\"41154395\", \"37219768\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"whether CDK4 and GSK3β act redundantly or in different contexts is unresolved\", \"TRIM17-mediated degradation confirmed in single lab only\", \"other E3 ligases targeting RBM38 not systematically surveyed\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"RBM38 was established as an essential regulator of erythroid terminal differentiation by jointly controlling alternative splicing, mRNA decay, and translation of ferrochelatase (Fech); Rbm38-deficient mice develop microcytic hypochromic anemia with protoporphyrin IX accumulation resembling erythropoietic protoporphyria, rescued by enforced Fech expression.\",\n      \"evidence\": \"Conditional Rbm38 KO mice, RNA-seq splicing analysis, mRNA stability and translation assays, Fech rescue transplantation\",\n      \"pmids\": [\"40961234\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"whether RBM38 mutations cause erythropoietic protoporphyria in humans is unknown\", \"full complement of erythroid splicing targets beyond EPB41 and Fech not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis for how RBM38 switches between mRNA stabilization and destabilization on different targets; the full-length protein structure including the C-terminal eIF4E/eIF4G-binding and Ago2-interacting regions; tissue-specific hierarchies among the multiple feedback loops; and whether human RBM38 loss-of-function mutations cause hematologic disease.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"no full-length RBM38 structure available\", \"no human genetic disease association established\", \"systematic transcriptome-wide identification of direct splicing versus stability versus translation targets not completed\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [0, 1, 2, 3, 4, 5, 6, 8, 11, 23]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 10, 20, 24, 25]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [11, 30, 31]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3, 10, 24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [0, 2, 5, 6, 8, 11, 30, 31]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [3, 10, 13, 25, 27]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [0, 7, 29]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [8, 12]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [2, 11, 29, 31]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"HuR\",\n      \"eIF4E\",\n      \"eIF4G\",\n      \"AGO2\",\n      \"PPM1D\",\n      \"TRIM17\",\n      \"GSK3B\",\n      \"RBM24\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}